|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0175659,
umls-concept:C0205489,
umls-concept:C0222045,
umls-concept:C0349674,
umls-concept:C0441800,
umls-concept:C0600688,
umls-concept:C0919553,
umls-concept:C1123023,
umls-concept:C1257890,
umls-concept:C1441414,
umls-concept:C1443775,
umls-concept:C1553874,
umls-concept:C1578820,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-3-2
|
|
pubmed:abstractText |
Accurate grading of dermatologic adverse events (AE) due to epidermal growth factor receptor (EGFR) inhibitors (EGFRIs) is necessary for drug toxicity determinations, interagent comparisons, and supportive care trials. The most widely used severity grading scale, the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0), was not designed specifically for this class of agents and may result in underreporting and poor grading of distinctive adverse events. We believe a class-specific grading scale is needed to help standardize assessment and improve reporting of EGFRI-associated dermatologic AEs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1433-7339
|
|
pubmed:author |
pubmed-author:BaranRobertR,
pubmed-author:BaraschAndreiA,
pubmed-author:BaschEthanE,
pubmed-author:ChenAliceA,
pubmed-author:DanceyJanet EJE,
pubmed-author:EabyBethB,
pubmed-author:EinhornLawrenceL,
pubmed-author:EpsteinJoel BJB,
pubmed-author:FoxLindy PLP,
pubmed-author:KrisMark GMG,
pubmed-author:KurtinSandraS,
pubmed-author:LacoutureMario EME,
pubmed-author:MaitlandMichael LML,
pubmed-author:OlsenElise AEA,
pubmed-author:RapoportBernardo LBL,
pubmed-author:SegaertSiegfriedS,
pubmed-author:SetserAnnA,
pubmed-author:TrottiAndyA,
pubmed-author:WagnerLynneL,
pubmed-author:WestDennis PDP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
509-22
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
|
|
pubmed:affiliation |
Dermatology Service, Rockefeller Outpatient Pavilion, Memorial Sloan-Kettering 53rd Street, 160 East 53rd Street, New York, NY 10022, USA. LacoutuM@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
